To confirm that our bumped compounds will not inhibit WT BET proteins at commonly used concentrations, nor alter the phenotypes of BET-sensitive cells we assayed the activity of our compounds on the viability of BET-dependent AML cell-lines MV4-11 and HL-60 (ref. 14) (Fig. 7). The gene discussed is DNER; the disease is acute myeloid leukemia.